                         SEQUENCE LISTING

<110>  Vaccinex, Inc.
       EVANS, Elizabeth
       SMITH, Ernest
       ZAUDERER, Maurice
 
<120>  TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION 
       WITH AN EPIGENETIC MODULATING AGENT

<130>  58008-172854

<150>  62/473,731
<151>  2017-03-20

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 VH

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gln Ile Asn Pro Thr Thr Gly Gly Ala Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Tyr Tyr Tyr Gly Arg His Phe Asp Val Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  2
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 HCDR1

<400>  2

Gly Tyr Ser Phe Ser Asp Tyr Tyr Met His 
1               5                   10  


<210>  3
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 HCDR2

<400>  3

Gln Ile Asn Pro Thr Thr Gly Gly Ala Ser Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  4
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 HCDR3

<400>  4

Tyr Tyr Tyr Gly Arg His Phe Asp Val 
1               5                   


<210>  5
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 VL

<400>  5

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


<210>  6
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 LCDR1

<400>  6

Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn 
1               5                   10                  15  


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 LCDR2

<400>  7

Ala Ala Ser Asn Leu Glu Ser 
1               5           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VX15/2503 LCDR3

<400>  8

Gln Gln Ser Asn Glu Asp Pro Tyr Thr 
1               5                   


<210>  9
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Mab 67 VH

<400>  9

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Ser Pro Glu Asn Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gln Ile Asn Pro Thr Thr Gly Gly Ala Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Lys Ser Leu Thr Ser Glu Glu Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Tyr Tyr Tyr Gly Arg His Phe Asp Val Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  10
<211>  111
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Mab 67 VL

<400>  10

Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 
            20                  25                  30          


Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 
65                  70                  75                  80  


Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 
                85                  90                  95      


Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110     


